* Novartis announces zykadia first-line study results
showing 16.6 month progression-free survival in patients with
ALK+ advanced NSCLC
The post BRIEF-Novartis’s Zykadia outperforms standard therapy in untreated lung cancer patients appeared first on NASDAQ.